Biden administration asserts power to seize drug patents in move to slash high prices

The Biden administration unveiled a new framework outlining the factors federal agencies should consider in determining whether to use march-in rights.

from Health and Science https://ift.tt/wnzvcAj
https://ift.tt/PGF1R6K
https://ift.tt/60Ruvdw